MedTech News
.................... by Andrew Celentano
How ‘good’ bacteria from fecal transplants reduce peanut allergy
Some 33 million Americans have severe food allergies. Now, researchers at Boston Children’s Hospital may have found a promising solution.
First-in-class small molecule inhibitor shows promise against pancreatic cancer in preclinical studies
Mayo Clinic researchers have developed an experimental drug with the help of artificial intelligence (AI) to target the “undruggable” PDZ domain of the GIPC1 protein, which helps different types of cancer, including pancreatic cancer, grow and resist treatment. In laboratory studies, the drug slowed tumor growth, improved survival and enhanced the effects of the chemotherapy drug gemcitabine.
A new drug that can potentially overcome cancer therapy resistance
Researchers at Baylor College of Medicine have developed a drug called CS18 that disrupts cancer cells’ ability to survive therapy. The findings, published in Science Advances, support exploring the possibility of using CS18 to treat human cancer in the future.
A lesser-known SARS-CoV-2 protein may offer clues to long COVID symptoms
Six years after the height of the COVID-19 pandemic, scientists are still uncovering surprising ways the virus can wreak havoc on the body. A new UCLA study published in Science Advances describes a previously unrecognized way the SARS-CoV-2 nucleocapsid protein—a structural protein less familiar than the spike protein that has dominated public attention and much vaccine research—can push the immune system into dangerous overdrive.
Engineered human neurons rebuild damaged spinal cord circuits
Spinal cord injuries affect an estimated 15 to 20 million people worldwide, often causing lasting impairments in movement, sensation and independence. Such injuries can be especially devastating when they occur at the level of the neck, where damaged spinal circuits disrupt signals that control the diaphragm, the main muscle used for breathing.
Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche’s VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma. The assay helps identify patients who may be eligible for treatment with AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone acetate and prednisone.
Koning Health Achieves MDSAP Certification
Certification strengthens Koning’s global regulatory foundation as two new Vera Breast CT systems expand patient access in key U.S. markets
Cortechs.ai Expands CE Marking Across AI Imaging Platform for European Market
Cortechs.ai, a San Diego, CA-based provider of AI-powered quantitative imaging solutions, has announced the expansion of its European CE Marking under the European Union Medical Device Regulation (EU MDR) for its latest imaging products.